Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Miralpeix, M. Aparici, C. Carcasona, I. Ramos, C. Puig, D. Vilella, A. Gavaldà (Barcelona, Spain). Abediterol has higher beta₂-receptor affinity and in vitro bronchodilatory potency than other long-acting beta₂-agonists, with good selectivity. Eur Respir J 2014; 44: Suppl. 58, 952

Member's Comments

No comment yet.

Related content which might interest you: Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2-agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Abediterol has higher bronchodilatory potency than other long-acting beta2-receptor agonists in a guinea pig model Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Abediterol, a novel long-acting inhaled beta2-agonist, has a fast association rate and long residence time at human beta2 receptors Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Synergistic effects by combination of tiotropium with olodaterol result from cross talk between muscarinic and β2-adrenergic receptors via allosteric modulation Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Translational study searching for synergy between glycopyrronium and indacaterol Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009 Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016